Kuros Biosciences’s licensee Checkmate Pharmaceuticals completes its IPO on NASDAQ
News 09.09.2020 Schlieren (Zurich), Switzerland, September 9, 2020 – Kuros Biosciences, a leader in next generation bone graft technologies, notes the successful initial public offering (IPO) on NASDAQ (NASDAQ: CMPI) of Checkmate Pharmaceuticals, which has licensed CMP-001, formerly known as CYT003, from Kuros. Checkmate raised gross proceeds of $75 million in its recent...